🇺🇸 FDA
Pipeline program

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

PRO-sPanFlu-2002

Phase 2 mab completed

Quick answer

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) for Influenza is a Phase 2 program (mab) at China SXT Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Influenza
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials